CHEBI:133017 - pimavanserin

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name pimavanserin
ChEBI ID CHEBI:133017
Definition A member of the class of ureas in which three of the four hydrogens are replaced by 4-fluorobenzyl, 1-methylpiperidin-4-yl, and 4-(isopropyloxy)benzyl groups. An atypical antipsychotic that is used (in the form of its tartrate salt) for treatment of hallucinations and delusions associated with Parkinson's disease.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C25H34FN3O2
Net Charge 0
Average Mass 427.556
Monoisotopic Mass 427.26351
InChI InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
InChIKey RKEWSXXUOLRFBX-UHFFFAOYSA-N
SMILES C1=C(C=CC(=C1)CNC(N(C2CCN(CC2)C)CC3=CC=C(C=C3)F)=O)OCC(C)C
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): 5-hydroxytryptamine 2A receptor inverse agonist
An inverse agonist that binds to the same receptor as a 5-hydroxytryptamine 2A receptor agonist, but which induces a pharmacological response opposite to that agonist.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
Application(s): antipsychotic agent
Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing pimavanserin (CHEBI:133017) has role 5-hydroxytryptamine 2A receptor inverse agonist (CHEBI:133016)
pimavanserin (CHEBI:133017) has role antipsychotic agent (CHEBI:35476)
pimavanserin (CHEBI:133017) has role serotonergic antagonist (CHEBI:48279)
pimavanserin (CHEBI:133017) is a aromatic ether (CHEBI:35618)
pimavanserin (CHEBI:133017) is a monofluorobenzenes (CHEBI:83575)
pimavanserin (CHEBI:133017) is a piperidines (CHEBI:26151)
pimavanserin (CHEBI:133017) is a tertiary amino compound (CHEBI:50996)
pimavanserin (CHEBI:133017) is a ureas (CHEBI:47857)
pimavanserin (CHEBI:133017) is conjugate base of pimavanserin(1+) (CHEBI:133020)
Incoming pimavanserin(1+) (CHEBI:133020) is conjugate acid of pimavanserin (CHEBI:133017)
IUPAC Name
N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea
INN Source
pimavanserin ChemIDplus
Synonym Source
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide ChemIDplus
Manual Xrefs Databases
5142 DrugCentral
CA2652300 Patent
Pimavanserin Wikipedia
View more database links
Registry Numbers Types Sources
10386699 Reaxys Registry Number Reaxys
706779-91-1 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
16469866 PubMed citation Europe PMC
19040345 PubMed citation Europe PMC
19864614 PubMed citation Europe PMC
19907417 PubMed citation Europe PMC
21256805 PubMed citation Europe PMC
21921840 PubMed citation Europe PMC
22750845 PubMed citation Europe PMC
22954754 PubMed citation Europe PMC
23969614 PubMed citation Europe PMC
24016069 PubMed citation Europe PMC
24183563 PubMed citation Europe PMC
24183566 PubMed citation Europe PMC
24247322 PubMed citation Europe PMC
24292660 PubMed citation Europe PMC
24682754 PubMed citation Europe PMC
25655720 PubMed citation Europe PMC
26744739 PubMed citation Europe PMC
26908168 PubMed citation Europe PMC
27242287 PubMed citation Europe PMC
27245248 PubMed citation Europe PMC
27249096 PubMed citation Europe PMC
27261226 PubMed citation Europe PMC
27262680 PubMed citation Europe PMC
27503570 PubMed citation Europe PMC
Last Modified
22 February 2017